Table 1.
Infectious disease vaccines receiving U.S. food and drug administration (FDA) approval since 1990 (excluding biodefense vaccines)
| Vaccine name | Infectious disease(s) | Vaccine type | Manufacturer | Year FDA approval | Starting price ($US) | Source | |
| JE-VAX⋄ | Japanese Encephalitis | Inactivated | Biken | 1992 | NA | 68 | |
| HAVRIX | Hepatitis A | Inactivated | GlaxoSmithKline Biologics (GSK) | 1995 | 28.45* | 68, 69 | |
| VARIVAX | Varicella Virus (ChickenPox) | Live | Merck | 1995 | 41.41* | 68, 69 | |
| Tripedia | Diptheria, Tetanus toxoids and acellular Pertussis (DTaP) | Toxoid | Sanofi Pasteur | 1996 | 19.43 | 68, 69 | |
| ActHIB | Haemophilus type b (hib B) | Conjugate | Sanofi Pasteur | 1996 | 14.5 | 68, 69 | |
| COMVAX | hib B and Hepatitis B (HBV) | Conjugate | Merck | 1996 | 43.56* | 68, 69 | |
| VAQTA | Hepatitis A (HAV) | Inactivated | Merck | 1996 | 44.49* | 68, 69 | |
| INFANRIX | DTaP | Toxoid | GSK | 1997 | 17.05 | 68, 69 | |
| ENERGIX-B | HBV | Recombinant | GSK | 1998 | 24.2 | 68, 69 | |
| LYMErix | Lyme Disease | Recombinant | GSK | 1998 | 61.25 | 27, 70 | |
| TICE BCG | Mycobacterium bovis | Live | Organon Teknika | 1998 | NA | 68 | |
| RotaShield† | Rotavirus | Live | Wyeth-Ayerst | 1998 | 30 | 71 | |
| RECOMBIVAX HB | HBV | Recombinant | Merck | 1999 | 20.37 | 68, 69 | |
| Prevnar | Pneumococcal | Conjugate | Wyeth | 2000 | 58 | 68, 69 | |
| TWINRIX | HAV & HBV | Inactivated Recombinant | GSK | 2001 | 78.67* | 68, 69 | |
| DAPTACEL | DTaP | Toxoid | Sanofi Pasteur | 2002 | 20.24 | 68, 69 | |
| PEDIARIX | DTaP, HBV, inactivated Poliovirus (IPV) | Toxoid | GSK | 2002 | 69.41* | 68, 69 | |
| FluMist | Influenza | Live | MedImmune | 2003 | 22.50* | 68, 69 | |
| ProQuad | Measles, Mumps, Rubella and Varicella | Live | Merck | 2005 | 117.6 | 68, 69 | |
| Menactra | Bacterial Meningitis | Conjugate | Sanofi Pasteur | 2005 | 82 | 68, 69 | |
| ADACEL | Tetanus toxoid, reduced Diphtheria toxoid, and acellular Pertussis (tdap) | Toxoid | Sanofi Pasteur | 2005 | 35.75 | 68, 69 | |
| BOOSTRIX | tdap | Toxoid | GSK | 2005 | 35.25 | 68, 69 | |
| GARDASIL | Human Papillomavirus (HPV) | Inactivated | Merck | 2006 | 119.75 | 68, 69 | |
| RotaTeq | Rotavirus | Live | Merck | 2006 | 63.25 | 68, 69 | |
| ZOSTAVAX | Herpes Zoster (Shingles) | Live | Merck | 2006 | 174* | 68, 72 | |
| KINRIX | DTaP & IPV | Toxoid | GSK | 2008 | 48 | 68, 69 | |
| Pentacel | DTaP, IPV, hib B conjugate | Toxoid | Sanofi Pasteur | 2008 | 72.91 | 68, 69 | |
| ROTARIX | Rotavirus | Live | GSK | 2008 | 102.5 | 68, 69 | |
| HIBERIX | hib B | Conjugate | GSK | 2009 | 22.83 | 68, 69 | |
| CERVARIX | Human Papillomavirus (HPV) | Inactivated | GSK | 2009 | - | 68 | |
| Ixiaro | Japanese Encephalitis | Inactivated | Intercell | 2009 | - | 68 |
All starting prices are the year of FDA approval unless otherwise noted. Excludes vaccines such as anthrax and plague vaccines licensed exclusively for military anti-bioterrorism use.
*
Starting price is the year after FDA approval.
†
Vaccine discontinued.
⋄
Vaccine no longer in production.